JNJ · News · 20260921N

Competition and Market Position

JOHNSON & JOHNSON · 2026-09-21 · Importance 17 · Surprise 24

Compass Pathways is preparing to launch COMP360, a psychedelic depression therapy, using interventional psychiatry clinic capacity that was substantially developed during Johnson & Johnson’s Spravato launch. Compass describes COMP360 as differentiated from Spravato by its infrequent dosing schedule and distinct patient experience. The report indicates that Spravato helped establish treatment infrastructure while COMP360 is targeting unmet psychiatric demand with a different administration model.

Key facts

• Johnson & Johnson's earlier launch of Spravato established an infrastructure of interventional psychiatry clinics that Compass Pathways is leveraging for its COMP360 psychedelic depression treatment launch. source